Cost-effectiveness of FreeO2 in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec

Objective

Conduct a cost-effectiveness analysis of FreeO₂ technology versus manual oxygen-titration technology for patients with chronic obstructive pulmonary disease (COPD) hospitalised for acute exacerbations.

Setting

Tertiary acute care hospital in Quebec, Canada.

Participants

47 patients with COPD hospitalised for acute exacerbations.

Intervention

An automated oxygen-titration and oxygen-weaning technology.

Methods and outcomes

The costs for hospitalisation and follow-up for 180 days were calculated using a microcosting approach and included the cost of FreeO₂ technology. Incremental cost-effectiveness ratios (ICERs) were calculated using bootstrap resampling with 5000 replications. The main effect variable was the percentage of time spent at the target oxygen saturation (SpO₂). The other two effect variables were the time spent in hyperoxia (target SpO₂+5%) and in severe hypoxaemia (SpO₂ <85%). The resamplings were based on data from a randomised controlled trial with 47 patients with COPD hospitalised for acute exacerbations.

Results

FreeO₂ generated savings of 20.7% of the per-patient costs at 180 days (ie, –$C2959.71). This decrease is nevertheless not significant at the 95% threshold (P=0.13), but the effect variables all improved (P<0.001). The improvement in the time spent at the target SpO₂ was 56.3%. The ICERs indicate that FreeO₂ technology is more cost-effective than manual oxygen titration with a savings of –$C96.91 per percentage point of time spent at the target SpO₂ (95% CI –301.26 to 116.96).

Conclusion

FreeO₂ technology could significantly enhance the efficiency of the health system by reducing per-patient costs at 180 days. A study with a larger patient sample needs to be carried out to confirm these preliminary results.

Trial registration number

NCT01393015; Post-results.

http://ift.tt/2E2cYqD